A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of
DBPR108 in subjects with mild or moderate hepatic impairment (HI) compared to the matched
control subjects with normal hepatic function.